Sputnik V receives DCGI approval, makes it 3rd corona vaccine for India


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
The supply of the third vaccine is bound to strengthen the Covid-19 vaccination drive across the country.

India on Monday approved Russian jab Sputnik V as the third Covid-19 vaccine for restricted use in the country. The vaccine was developed by the Gamaleya Research Institute (GRI) of Russia, and funded and promoted outside by the Russian Direct Investment Fund (RDIF).

In India, the RDIF's partner is Dr Reddy's Laboratories, which conducted clinical trials - mandatory for approval - India. Sputnik-V became the first vaccine to be announced last year for protection against Covid-19.

It works on complex biotechnology in which another virus is employed to carry the DNA code required for triggering an immune response in human cells. Sputnik V's approval has come at a time when the country is reeling under a shortage of existing two vaccines - Covishield and Covaxin.

India has a combined production capacity of around 6.40 crore doses a month of the two approved vaccines in a month. Covishield-maker Serum Institute of India (SII) is shouldering the major burden as the other vaccine-manufacturer, the Bharat Biotech has a limited capacity of 40 lakh doses a month.

Several states have flagged in recent days that both Covishield and Covaxin are in short supply. Reports of vaccination centres from Varanasi in Uttar Pradesh to Mumbai in Maharashtra appeared last week.

Vaccine shortage became an issue of a political fight between the Centre and the Opposition-ruled governments in the backdrop of the second wave of Covid-19 pandemic wreaking havoc in at least 10 states. Maharashtra, Delhi, Chhattisgarh, Punjab, Madhya Pradesh, Kerala, and Uttar Pradesh are among severely impacted states.

The supply of the third vaccine is bound to strengthen the Covid-19 vaccination drive across the country.

Sputnik V, named after the first Soviet space satellite, showed a better efficacy during trials compared to the vaccines already in use in India. Both Covishield and Covaxin showed the efficacy of around 81 per cent in the trials, Sputnik V returned with 91-92 per cent efficacy.

On the production front, the Russian Direct Investment Fund (RDIF) has tied up with Indian pharmaceutical firms such as Dr Reddy's Laboratories, Hetero Biopharma, Gland Pharma, Stelis Biopharma and Vichrow Biotech for the manufacturing the vaccine doses.

These firms jointly have an annual production capacity of 850 million doses for Sputnik V. This makes Sputnik V's approval a big shot in the arm in the fight against the Covid-19 pandemic.

It is expected that the doses of the Sputnik V vaccine will be available at vaccination centres by June this year. There are at least four more vaccines that are expected to get approval from the Drug Controller General of India (DCGI) by the year-end.







Tags : #SputnikV #RussianVaccineforCorona #EfficacyofRussianVaccine #DrReddysLab #SerumInstituteofIndia #BharatBiotech #DCGI #LatestNewsonCOVIDVaccine13thApr

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026